IMNM - Company ID 0001472012
The table below shows Immunome Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$58.64M | -$53.05M | -$11.17M | $24.17M | -$6.38M | -$3.54M |
| Capital expenditure | $3.00M | $3.67M | $2.16M | $106.00K | $6.00K | $31.00K |
| Investing cash flow | -$12.02M | $5.09M | -$37.23M | -$106.00K | -$6.00K | -$31.00K |
| Dividends paid | - | - | - |
Immunome Inc. reported operating cash flow of -$190.92M for fiscal year 2025. That is down 72.3% from -$110.79M in fiscal 2024. Over the 7 fiscal years shown, operating cash flow declined from -$9.60M (FY 2019) to -$190.92M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | -$135.00K | $162.23M | $219.44M | $34.00K | $32.00K | $76.00K |